SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Dynavax Technologies Corporation

Levi & Korsinsky announces it has commenced an investigation of Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX) concerning possible violations of federal securities laws by certain officers and directors.

On November 14, 2016, Dynavax fell more than 62% on intraday trading following an announcement that the Company had received a Complete Response Letter from the U.S. Food and Drug Administration. According to Dynavax, the CRL requests further information on several topics "including clarification regarding specific adverse events of special interest (AESIs), a numerical imbalance in a small number of cardiac events in a single study (HBV-23), new analyses of the integrated safety data base across different time periods, and post-marketing commitments." To obtain additional information about the investigation, go to:

http://zlk.9nl.com/dynavax

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161114006126/en/
Copyright Business Wire 2010

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

Small-Cap Turnaround Stories

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round